Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-LNC1007
- Development stage
- Phase 1
- Lead developer
- Yantai Lannacheng Biotechnology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-LNC1007 is a radiopharmaceutical diagnostic agent designed for positron emission tomography (PET) imaging. It is a heterodimer tracer that targets both fibroblast activation protein (FAP) and integrin αvβ3, which are highly expressed in cancer-associated fibroblasts and angiogenic tumor cells, respectively. The compound is synthesized from FAP inhibitor-02 (FAPI-02) and cyclic arginine-glycine-aspartate (RGD), enabling dual-targeted imaging of solid tumors. Preclinical studies and initial clinical investigations indicate that it provides higher sensitivity and specificity for detecting primary lesions and metastases in various cancers—including renal cell carcinoma—compared to standard tracers like FDG or PSMA PET/CT. The drug is being developed by Yantai LNC Biotechnology, with planned phase I trials in adults with solid tumors[1][2][3][4][5][6].
- Other names
- 68Ga-LNC100768-Ga LNC 100768Ga-FAPI-RGD
02
Targets
FAP (Fibroblast activation protein alpha)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on 68Ga-LNC1007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-LNC1007.